Tech Company Financing Transactions
Enveda Biosciences Funding Round
Enveda Biosciences secured a $51 million Series A funding round on 4/25/2023. Investors included Kinnevik, Dimension and FPV Ventures.
Transaction Overview
Company Name
Announced On
4/25/2023
Transaction Type
Venture Equity
Amount
$51,000,000
Round
Series A
Investors
Proceeds Purpose
The funding will enable Enveda to progress multiple platform-derived molecules to the clinic in 2023 and 2024 across inflammation, fibrosis, and neurosensory indications.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1880 S Flatiron Ct. K
Boulder, CO 80301
USA
Boulder, CO 80301
USA
Phone
Website
Email Address
Overview
At Enveda, we're harnessing the complexity of the natural world to tackle today's biggest healthcare challenges. With the help of breakthrough advancements in knowledge graphs, machine learning, and metabolomics, we're discovering the next generation of small molecules.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Viswa Colluru
Chief Scientific Officer
Sotirios Karathanasis
Chief Technical Officer
Joseph Rokicki
Vice President
David Healey
Vice President
Bryan Norman
VP - Administration
Daniel Wee
VP - Engineering
Chris Diana
VP - Product Management
Hannah Gordon
Browse more venture capital transactions:
Prev: 4/25/2023: Veo Robotics venture capital transaction
Next: 4/26/2023: aiXplain venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs